News round-up for 11-15 August by DDW Senior Digital Content Editor Diana Turner.

This week has seen some incredible advances in immunotherapy, including the development of a therapy that combines natural killer and CAR-T cells, and an off-the-shelf cancer vaccine that could revolutionise treatment for patients with one of the most common cancer-driving mutations.

The top stories:

Strand Therapeutics raises $153 million for mRNA therapies

Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.

Read more…

Faron reports 43% complete remission rate in MDS

Faron Pharmaceuticals has announced an increase in the complete remission (CR) rate in patients with frontline or treatment-naïve high-risk myelodysplastic syndrome (HR-MDS), based on updated efficacy data from its Phase I/II BEXMAB trial.

Read more…

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).

Read more…

Off-the-shelf cancer vaccine shows promise in KRAS-driven cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer.

Read more…

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.

Read more…